Correction: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). BMJ Publishing Group.
Chicago Style (17th ed.) CitationCorrection: Phase I Studies of Davoceticept (ALPN-202), a PD-L1-dependent CD28 Co-stimulator and Dual PD-L1/CTLA-4 Inhibitor, as Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors (NEON-1 and NEON-2). BMJ Publishing Group.
MLA (9th ed.) CitationCorrection: Phase I Studies of Davoceticept (ALPN-202), a PD-L1-dependent CD28 Co-stimulator and Dual PD-L1/CTLA-4 Inhibitor, as Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors (NEON-1 and NEON-2). BMJ Publishing Group.